Le Lézard
Classified in: Health
Subject: TRI

Biomarker data from the fostroxacitabine bralpamide phase 1 study to be presented at the EASL Liver Cancer Summit


STOCKHOLM, Jan. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR-B) today announces that an e-poster entitled "Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver" will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit 3-4 February. The Abstract (PO-221) is available on the EASL website (https://easl.eu/wp-content/uploads/2022/01/LCS-2022-Abstract-book-final.pdf).

For additional information, please contact
Magnus Christensen, Interim CEO and CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected]

About fostroxacitabine bralpamide
Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostroxacitabine bralpamide has completed a phase 1b monotherapy study, and a combination study in HCC was recently initiated.

About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (MIV-818), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (Stockholm: MVIR-B) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/biomarker-data-from-the-fostroxacitabine-bralpamide-phase-1-study-to-be-presented-at-the-easl-liver-,c3490352

The following files are available for download:

https://mb.cision.com/Main/652/3490352/1523531.pdf

Press release (PDF)

 

SOURCE Medivir


These press releases may also interest you

at 23:41
SIMCERE PHARMA (HK.2096)  announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute of Materia Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the...

at 22:20
The Sasakawa Peace Foundation (SPF), Citizen's Network for Global Activities (CINGA), and Forum for Refugees Japan (FRJ), are pleased to announce the opening of the Support Center for Refugees Japan (Support-R) in Tokyo on May 19, 2022. Russia's...

at 22:10
Global superstar and immersive entrepreneur, J Balvin, has announced the creation of OYE, the new bilingual, interactive wellness app. Balvin, the company's co-founder and Chief Dream Officer, co-founded OYE with happiness activist and ed-tech...

at 22:05
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its...

at 20:25
Cari M. Schwartz has been and is, currently, involved with many non-profit organizations that focus on healthcare needs of people across the country. As a Partner Attorney at Kantor & Kantor, LLP, it is her passion to bring education about patient's...

at 19:05
Imugene Limited , a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating...



News published on 21 january 2022 at 08:55 and distributed by: